List of Excipients in Branded Drug LIVDELZI

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	61958-3301	BUTYLATED HYDROXYTOLUENE	2031-08-14
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	61958-3301	CROSCARMELLOSE SODIUM	2031-08-14
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	61958-3301	MAGNESIUM STEARATE	2031-08-14
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	61958-3301	MANNITOL	2031-08-14
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	61958-3301	MICROCRYSTALLINE CELLULOSE 101	2031-08-14
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	61958-3301	MICROCRYSTALLINE CELLULOSE 302	2031-08-14

Livdelzi Excipient Strategy and Commercial Opportunities: Seladelpar Formulation, Generic Risk, and Patent Outlook

Last updated: October 13, 2026

Livdelzi (seladelpar) is a once-daily, 10 mg oral capsule approved by the FDA for adults with primary biliary cholangitis (PBC) who have an inadequate response to or intolerance of ursodeoxycholic acid (UDCA). Its formulation uses conventional oral solid-dose excipients, creating limited near-term opportunity for differentiated excipient suppliers but meaningful opportunities in generic development, alternative dosage forms, stability enhancement, and patient-friendly delivery systems.

The commercial value of Livdelzi is driven primarily by seladelpar’s active pharmaceutical ingredient, clinical positioning, orphan-drug status, and use in PBC rather than by a complex formulation. The most relevant excipient opportunities involve capsule manufacturing, powder-flow control, low-dose content uniformity, moisture protection, and future pediatric or dysphagia-friendly presentations.

What is Livdelzi and how is it formulated?

Livdelzi contains seladelpar, a selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist. The FDA-approved product is a 10 mg capsule administered once daily, with or without food. The approved indication is PBC in adults with inadequate response to UDCA or intolerance to UDCA. Livdelzi is marketed by Gilead Sciences following its acquisition of CymaBay Therapeutics in 2024. [1,2]

The FDA prescribing information identifies the following inactive ingredients:

Formulation element	Publicly identified material
Capsule fill	Colloidal silicon dioxide
Capsule fill	Croscarmellose sodium
Capsule fill	Magnesium stearate
Capsule fill	Microcrystalline cellulose
Capsule fill	Sodium lauryl sulfate
Capsule shell	Gelatin
Capsule shell	Titanium dioxide
Capsule shell	FD&C Blue No. 1

The formulation is a conventional immediate-release hard gelatin capsule. It does not rely on an extended-release matrix, lipid-based delivery system, enteric coating, amorphous solid dispersion, or biologic stabilization platform. [1]

What does each Livdelzi excipient do?

Microcrystalline cellulose is the principal diluent and contributes to capsule-fill bulk, compressibility, and powder handling. Croscarmellose sodium acts as a superdisintegrant and supports rapid capsule-fill dispersion. Colloidal silicon dioxide improves flow and reduces powder cohesion. Magnesium stearate functions as a lubricant during manufacturing.

Sodium lauryl sulfate is a wetting agent that may improve interaction between the drug substance and dissolution media. This is relevant because low-dose formulations can be sensitive to poor wetting, particle-size variation, and hydrophobic behavior introduced by lubricant overuse.

The capsule shell uses gelatin, titanium dioxide, and FD&C Blue No. 1 for shell formation, opacity, and color. These materials are established pharmaceutical ingredients, but gelatin creates potential market-access requirements for vegetarian, vegan, religious, and certain geographic markets.

What excipient strategy does Livdelzi use?

Livdelzi uses a risk-controlled, conventional excipient strategy rather than a formulation-led product differentiation strategy.

The formulation priorities are likely:

1. Achieving uniform distribution of a low-dose active ingredient.
2. Maintaining powder flow during capsule filling.
3. Controlling lubrication without slowing dissolution.
4. Ensuring rapid disintegration and drug release.
5. Protecting the product from moisture and manufacturing variability.
6. Supporting scalable commercial production with widely available excipients.

The 10 mg strength makes blend uniformity a central manufacturing issue. Seladelpar represents a small proportion of the total capsule fill, so particle-size distribution, geometric dilution, blending time, segregation control, and sampling design are important to content-uniformity performance.

Why sodium lauryl sulfate matters

Sodium lauryl sulfate can improve wetting and dissolution for poorly wettable drug particles. Its inclusion also creates a potential development variable for generic manufacturers. A generic product may use a different surfactant or omit sodium lauryl sulfate if it can demonstrate equivalent dissolution and bioequivalence.

The commercial opportunity for excipient suppliers is strongest where they can provide:

• Controlled particle-size grades.
• Low-peroxide and low-moisture materials.
• Direct-compression or capsule-fill grades of microcrystalline cellulose.
• High-purity colloidal silicon dioxide.
• Lubricants with predictable impact on dissolution.
• Surfactants with consistent wetting performance.
• Non-animal capsule-shell systems.

A supplier that can reduce blend segregation or improve capsule-fill weight variation may have a stronger value proposition than a supplier offering a nominally interchangeable standard excipient.

What formulation patents protect Livdelzi?

Publicly available product information indicates that Livdelzi’s commercial protection is centered mainly on seladelpar, its therapeutic use, and regulatory exclusivity rather than on a highly complex excipient platform.

The public label does not identify a proprietary excipient technology, novel release mechanism, or branded capsule-shell system. The listed excipients are common pharmaceutical materials. That reduces the likelihood that a generic entrant would face a major formulation barrier from the excipient composition alone.

Patent protection may still cover:

• Seladelpar composition and chemical forms.
• Methods of treating PBC.
• Methods involving biochemical or clinical response criteria.
• Dosing regimens.
• Crystalline, salt, or polymorphic forms.
• Manufacturing processes for seladelpar.
• Pharmaceutical compositions containing seladelpar.

Patent scope must be assessed claim by claim. A generic manufacturer can often design around a formulation claim by changing the filler, disintegrant, lubricant, surfactant, capsule shell, or manufacturing sequence, provided the resulting product satisfies FDA pharmaceutical-equivalence and bioequivalence requirements.

When does Livdelzi lose exclusivity?

Livdelzi has multiple layers of protection with different end dates.

Protection category	Event or expected period
FDA approval	August 14, 2024
Orphan-drug exclusivity	Seven years from approval, expected through August 2031, subject to statutory conditions
New chemical entity exclusivity	Five years from approval, expected through August 2029
Patent protection	Depends on issued patents, listed claims, patent-term adjustment, and any patent-term extension
Regulatory exclusivity	May be supplemented by pediatric or other FDA-granted exclusivity if awarded

FDA approved Livdelzi through the accelerated-approval pathway based on biochemical response, including reductions in alkaline phosphatase. Continued approval depends on postmarketing confirmation of clinical benefit. [1]

Orphan-drug exclusivity generally prevents FDA approval of the same drug for the same indication during the exclusivity period, subject to exceptions. It does not prevent all competition involving different active ingredients, different indications, or potentially different legal pathways.

The exact generic-entry date cannot be determined from orphan exclusivity alone. A generic or 505(b)(2) applicant may face listed patents, regulatory exclusivity, orphan-drug restrictions, and litigation outcomes that produce different practical launch dates.

What is the Orange Book status of Livdelzi?

Livdelzi is an FDA-approved prescription drug subject to Orange Book evaluation. The Orange Book is the controlling public source for identifying listed patents, patent expiration dates, use codes, and approved product information relevant to an abbreviated new drug application (ANDA). [3]

The key commercial questions are whether Gilead has listed:

• Drug-substance patents.
• Drug-product patents.
• Method-of-use patents.
• Formulation or dosage-regimen patents.
• Patent claims with expiration dates beyond the five-year NCE period.

For generic applicants, the important distinction is between composition or product claims and method-of-use claims. A method-of-use patent may be addressable through a section viii statement if the patented indication can be carved out, but that strategy depends on the FDA-approved labeling and the scope of the patent use code.

A full commercial diligence review should compare every Orange Book-listed patent against:

• Patent expiry and patent-term adjustment.
• Approved labeling.
• Use codes.
• Potential paragraph IV certification.
• Possibility of a skinny-label launch.
• Orphan-drug restrictions.
• Hatch-Waxman litigation risk.

Which companies are likely to challenge Livdelzi?

Generic pharmaceutical companies with established PBC, hepatology, or specialty-GI portfolios are the most logical future applicants. The likely applicant profile includes companies with:

• ANDA development capabilities.
• Access to seladelpar active pharmaceutical ingredient.
• Experience with low-dose oral capsules.
• Capacity to conduct comparative pharmacokinetic studies.
• Regulatory infrastructure for complex or orphan-disease products.

The first paragraph IV filer could obtain 180-day exclusivity if statutory requirements are satisfied and the applicant is otherwise eligible. That incentive may be limited by the relatively small PBC patient population, the need to source or manufacture seladelpar, and the possibility that orphan-drug exclusivity delays approval.

No biosimilar pathway applies to Livdelzi because seladelpar is a small-molecule drug, not a biologic. Competitive risk is therefore centered on generics, 505(b)(2) products, alternative PPAR agonists, and branded therapies for PBC.

What commercial opportunities exist for excipient suppliers?

1. Generic capsule development

The most immediate opportunity is supplying excipients for generic seladelpar capsules. A generic manufacturer may replicate the functional profile of the reference product without using identical excipient grades.

Potential supplier categories include:

Need	Commercial opportunity
Powder flow	Colloidal silicon dioxide and engineered flow aids
Blend uniformity	Low-segregation microcrystalline cellulose grades
Disintegration	High-performance croscarmellose sodium
Wetting	Sodium lauryl sulfate or alternative surfactants
Lubrication	Low-impact magnesium stearate grades
Capsule shell	Hypromellose or pullulan alternatives to gelatin
Stability	Low-moisture packaging and moisture-control systems

The highest-value suppliers will offer performance data tied to dissolution, blend uniformity, fill-weight control, and stability rather than simply selling commodity excipients.

2. Vegetarian and regional capsule-shell alternatives

The current gelatin shell may limit positioning in markets or patient populations that prefer non-animal capsules. Hypromellose capsules could provide a differentiated alternative if they preserve dissolution, mechanical performance, stability, and bioequivalence.

A non-gelatin capsule would not automatically create patent freedom or regulatory advantage. The applicant would still need to demonstrate pharmaceutical equivalence and bioequivalence. The opportunity is commercial and market-access oriented, not necessarily patent based.

3. Pediatric and dysphagia-friendly products

PBC is primarily an adult disease, but future development could examine formulations for patients with swallowing limitations or broader hepatology use. Potential dosage forms include:

• Sprinkle capsules.
• Mini-tablets.
• Oral powders.
• Reconstitutable suspensions.
• Liquid-filled capsules.
• Orally disintegrating tablets.

These formats would create greater excipient differentiation than the current hard capsule. They could also generate new formulation, manufacturing, and method-of-use patent opportunities.

A liquid formulation would require careful evaluation of solubility, suspension uniformity, chemical stability, preservative compatibility, taste, and container closure. The value proposition is strongest if the formulation solves a documented adherence or administration problem.

4. Stability and packaging systems

Excipient suppliers can also target product stability. Relevant technologies include:

• Desiccant-integrated bottles.
• High-barrier blister films.
• Moisture-scavenging closures.
• Low-moisture capsule shells.
• Oxygen-control packaging.
• Excipient grades with tighter water-activity specifications.

Packaging claims may be easier to design around than active-ingredient patents, but their commercial value depends on demonstrated shelf-life improvement and manufacturing savings.

How strong is the Livdelzi formulation estate?

The formulation estate appears moderate rather than exceptionally strong based on the public dosage form and ingredient profile.

Factor	Assessment
Dosage form complexity	Low to moderate
Excipient novelty	Low based on disclosed ingredients
Low-dose uniformity challenge	Moderate
Dissolution sensitivity	Moderate
Capsule-shell differentiation	Available
Manufacturing know-how	Moderate
API and clinical-use protection	More significant than excipient protection
Generic design-around potential	Relatively high at the excipient level

The principal barrier for a generic manufacturer is likely access to seladelpar, regulatory exclusivity, patent claims, and market economics rather than inability to reproduce the capsule excipient system.

What patent litigation and settlement risks affect Livdelzi?

The main litigation scenario would involve a paragraph IV challenge to an Orange Book-listed patent. Possible outcomes include:

• Settlement with a licensed or delayed generic launch.
• A court ruling invalidating or narrowly construing a patent.
• A finding of infringement that delays generic entry.
• A negotiated launch date before patent expiry.
• A launch after orphan-drug or NCE exclusivity ends.
• A carve-out strategy for patented methods of use.

Settlement terms may include restrictions on launch timing, licensing rights, authorized-generic arrangements, or supply relationships. No settlement should be assumed without a publicly filed agreement, court docket, or SEC disclosure.

How does Livdelzi compare with competing PBC therapies?

Product or class	Active ingredient	Formulation profile	Competitive relevance
Livdelzi	Seladelpar	10 mg hard capsule	PPAR-delta agonist for PBC
Ocaliva	Obeticholic acid	Oral tablet	Competing PBC product; FDA safety and indication changes affect positioning
Ursodiol/UDCA	Ursodeoxycholic acid	Multiple oral dosage forms	Standard first-line therapy
Fibrates, off-label	Bezafibrate or fenofibrate	Oral solid dosage forms	Alternative or adjunctive use in selected markets
Emerging agents	Various	Oral or injectable	Future competitive pressure

Livdelzi’s commercial positioning depends on tolerability, biochemical response, pruritus outcomes, use after UDCA failure, and access to specialty hepatology prescribers. Excipient differentiation is secondary to clinical performance and reimbursement.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible:

1. A delayed launch after NCE, orphan-drug, and patent barriers expire.
2. An earlier launch following successful paragraph IV litigation or settlement.
3. A limited-label launch using a method-of-use carve-out.

The first generic product could obtain a meaningful share if it offers lower pricing, broad payer access, and reliable supply. However, the orphan indication and specialty distribution model may reduce the absolute revenue available to multiple generic entrants.

Gilead’s commercial exposure will depend on the size of the PBC-treated population, persistence of use, payer restrictions, price, and any expansion into broader liver-disease populations. The company’s strongest defense is likely the combined effect of clinical differentiation, regulatory exclusivity, patents, and specialty commercialization rather than the capsule excipient composition.

Key Takeaways

• Livdelzi is a once-daily 10 mg seladelpar hard gelatin capsule.
• Its disclosed excipients are conventional: microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, and standard capsule-shell materials.
• The strongest excipient opportunities are in blend uniformity, dissolution control, moisture protection, capsule-shell alternatives, and future patient-friendly dosage forms.
• The product’s principal protection is expected to arise from seladelpar patents, therapeutic-use claims, regulatory exclusivity, and orphan-drug status.
• FDA approval occurred on August 14, 2024. NCE exclusivity is expected to run to approximately August 2029, while orphan-drug exclusivity is expected to run to approximately August 2031, subject to statutory conditions.
• Livdelzi has no biosimilar risk because seladelpar is a small molecule.
• Generic risk will depend on Orange Book listings, paragraph IV filings, patent litigation, settlement terms, API supply, and the economics of the PBC market.
• A non-gelatin capsule, sprinkle product, mini-tablet, or liquid formulation could create the most credible future excipient-led differentiation.

FAQs About Livdelzi Excipient and Commercial Strategy

Does Livdelzi contain lactose?

The FDA prescribing information lists microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, gelatin, titanium dioxide, and FD&C Blue No. 1. Lactose is not listed among the inactive ingredients. [1]

Can a generic Livdelzi use different excipients?

Yes. An ANDA applicant generally does not need to use identical excipients, but the proposed product must meet FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, and labeling.

Is Livdelzi a biologic subject to biosimilar competition?

No. Livdelzi contains seladelpar, a small-molecule active ingredient. Competition would proceed through generic or other small-molecule pathways rather than the biosimilar pathway.

Could Livdelzi be reformulated as a tablet?

Potentially. A tablet, mini-tablet, orally disintegrating tablet, or sprinkle product would require formulation development and regulatory support. The product would need to demonstrate acceptable performance and, depending on the regulatory pathway, bioequivalence or clinical bridging.

Which excipient is most important for generic Livdelzi?

The most strategically important excipient variables are likely microcrystalline cellulose for blend and fill performance, croscarmellose sodium for disintegration, sodium lauryl sulfate for wetting, and magnesium stearate because excessive lubrication can affect dissolution.

References

1. U.S. Food and Drug Administration. (2024). Livdelzi (seladelpar) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217899s000lbl.pdf

2. Gilead Sciences, Inc. (2024). Gilead Sciences completes acquisition of CymaBay Therapeutics. https://www.gilead.com/news-and-press/press-room/press-releases/2024/4/gilead-sciences-completes-acquisition-of-cymabay-therapeutics

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm